CureVac N.V. revenue breakdown overview

CureVac N.V. revenue for the last year amounted to 59.33 M USD, the most of which — 58.12 M USD — came from its highest performing source at the moment, Transformative Medicines Based on Messenger Ribonucleic Acid, the year earlier bringing 70.86 M USD. The greatest contribution to the revenue figure was made by Belgium — last year it brought CureVac N.V. 50.95 M USD, and the year before that — 65.44 M USD.